CureDuchenne, a nonprofit advocacy group that supports and promotes research and better care and for people with Duchenne…
Articles by Janet Stewart, MSc
The Pacific Northwest chapter of the FSH Society is holding its first-ever “Walk & Roll to Cure FSHD” event Sept.
Acceleron’s ACE-083, for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD), has been granted orphan drug status…
PTC Therapeutics announced the start of its fourth annual STRIVE awards program for Duchenne muscular dystrophy (DMD). STRIVE…
Expansion Therapeutics has raised $55.3 million in Series A financing to advance its portfolio of drugs targeting…
Researchers tracked the way adult skeletal muscle stem cells (MuSCs) multiply in response to aging or injury. The study has…
Summit Therapeutics announced the completion of a 24-week dosing period of ezutromid, its investigational therapy for patients with Duchenne…
Exonics Therapeutics has secured $40 million in financing from The Column Group (TCG) — a science-driven venture capital firm — to…
Results from the HOPE-1 trial of Capricor Therapeutics’ cell-based therapy CAP-1002 to treat boys and…
The U.S. Food and Drug Administration decided not to approve Translarna (ataluren), by PTC Therapeutics, as a treatment for specific…